2012
DOI: 10.5966/sctm.2011-0030
|View full text |Cite
|
Sign up to set email alerts
|

Concise Review: Cell Therapy and Tissue Engineering for Cardiovascular Disease

Abstract: ABSTRACT

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
27
0

Year Published

2013
2013
2018
2018

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(27 citation statements)
references
References 68 publications
(96 reference statements)
0
27
0
Order By: Relevance
“…(D,H)]. VEGF, a strong angiogenesis cytokine, is generally thought to be an important paracrine factor for improving damaged myocardium after transplantation of myoblast sheets . Those results showed that the cell sheets could adhere after centrifugation without any damage to the cells.…”
Section: Resultsmentioning
confidence: 97%
See 1 more Smart Citation
“…(D,H)]. VEGF, a strong angiogenesis cytokine, is generally thought to be an important paracrine factor for improving damaged myocardium after transplantation of myoblast sheets . Those results showed that the cell sheets could adhere after centrifugation without any damage to the cells.…”
Section: Resultsmentioning
confidence: 97%
“…The effectiveness of cell sheet‐therapy has already been shown in various animal models of damaged heart, so that clinical researches using autologous myoblast sheets are now underway for treating severe heart disease at three institutions, including Osaka University in Japan . The therapeutic effect is thought to be mainly due to the paracrine effect of factors, including VEGF produced from transplanted cell sheets . In the first clinical research using autologous myoblast sheets for supplying a large number of cells, quadruple‐layered myoblast sheets prepared from a 100 mm‐diameter temperature‐responsive culture dish, are transplanted onto five areas of the heart, for a total of 20 cell sheets .…”
Section: Discussionmentioning
confidence: 99%
“…Confluently cultured cells can be harvested as intact cell sheets using the dishes. Several cell sheets, including cardiac cell sheets, myoblast sheets, cardiac progenitor cell sheets and mesenchymal stem cell sheets, have been applied to regenerating damage cardiac tissue in various animal models and clinical trials using autologous myoblast sheets have also been started (Matsuura et al ., ; Shimizu et al ., ; Haraguchi et al ., ; Sawa et al ., ). In addition, cardiac cell sheets using mouse and human PSC‐derived cardiomyocytes for heart repair and the creation of engineered cardiac tissue have already been reported (Matsuura et al ., , ; Masumoto et al ., ).…”
Section: Introductionmentioning
confidence: 97%
“…In recent years, an increased number of patients have died from cardiovascular disease, which leads to an increasing clinical demand for tissue-engineered blood vessel (TEBV). 1,2 Endothelialization and inflammation are both crucial for TEBV patency. TEBV scaffold materials mostly comprise allograft acellular material or polymers, such as poly(lactic-co-glycolic) acid (PLGA).…”
Section: Introductionmentioning
confidence: 99%